Key terms
About MBRX
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company. It engages in the business of growing a pipeline including phase 2 clinical programs for hard-to-treat cancers and viruses. The company was founded by Walter V. Klemp, Donald H. Picker, and Waldemar Priebe on July 28, 2015 and is headquartered in Houston, TX.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest MBRX news
Mar 25
3:12pm ET
Moleculin Biotech Shares Corporate Update Presentation
Mar 25
10:41am ET
Moleculin Biotech trading resumes
Mar 25
10:36am ET
Moleculin Biotech trading halted, volatility trading pause
Mar 25
7:42am ET
Moleculin Biotech Announces Clinical Program Progress Updates
Mar 25
7:32am ET
Moleculin Biotech announces interim data on MB-106
Mar 21
7:50pm ET
Moleculin Biotech trading halted, news pending
Mar 20
7:42am ET
Moleculin Biotech 2023 Financial Results Announcement and Webcast
Mar 19
4:32pm ET
Moleculin Biotech announces reverse stock split
Feb 29
8:43am ET
Moleculin Biotech Hosts Virtual Investor Strategy Call
Feb 22
9:45am ET
Moleculin Biotech’s Leadership Shares Company Insights
Feb 15
9:32am ET
Moleculin Biotech Virtual Update with CEO Walter Klemp
Feb 14
4:54pm ET
Moleculin Biotech Shares Corporate Update Online
Feb 14
4:43pm ET
Moleculin Biotech Stockholders Endorse Key Financial Proposals
Feb 02
5:07pm ET
Moleculin Biotech files to sell 14.09M shares of common stock for holders
Jan 25
2:05pm ET
Moleculin Biotech: A Strong Buy on Breakthrough Annamycin Trial Results
Jan 25
4:13am ET
Moleculin Biotech Unveils Annamycin Trial Progress and 2024 Outlook
Jan 24
9:03am ET
Moleculin Biotech reports expected upcoming milestones for 2024
Jan 24
8:58am ET
Moleculin Biotech reports preliminary data on 2023-end annamycin clinical trials
Dec 29
11:00am ET
Biotech Alert: Searches spiking for these stocks today
Dec 27
8:03am ET
Moleculin Biotech CEO buys $130K in common stock
No recent news articles are available for MBRX
No recent press releases are available for MBRX
MBRX Financials
Key terms
Ad Feedback
MBRX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
MBRX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range